3 min read
In February 2026, FDA activity included new draft guidances, regulatory initiatives (e.g., PreCheck and eCTD 4.0), continued focus on innovation areas like rare diseases and AI, multiple drug approvals (including new molecular entities), and an upcoming...
2 min read
Developing advanced therapies for neurology is often described as a “perfect storm of complexity.” These studies face scientific, operational, and ethical challenges that require careful planning from the earliest stages.
2 min read
In life, specialized knowledge is required when guesswork is not an option.
3 min read
January 2026 regulatory updates underscored evolving AI-focused policies, ongoing scrutiny of evidentiary standards, strengthened compliance expectations, several product approvals, and advanced review modernization initiatives. The month also introduced...
4 min read
Each rare disease may affect only a few thousand, or even a few dozen, people worldwide. Yet together, rare conditions impact millions of patients and families. Developing effective therapies for these populations is one of the most complex and...
4 min read
December 2025 capped the year with a robust slate of FDA activity, including multiple final and draft guidances addressing labeling, safety reporting, clinical trials, and real-world evidence, alongside notable regulatory news and multiple drug and...
4 min read
4 min read
Following the political agreement of 11 December 2025 on the EU Pharmaceutical Package, the summary below highlights the elements most relevant to clinical evidence generation and Joint Clinical Assessment (JCA) planning. This reform represents the most...
4 min read
Mergers and acquisitions (M&As) are a defining feature of today’s biopharmaceutical landscape. As companies merge pipelines, teams, and strategies, clinical development programs often undergo significant transitions. Yet during these shifts, one of the...
4 min read
Returning from the American Society of Hematology Annual Meeting in Orlando, one message was clear: hematology is entering a phase of rapid diversification. Across late-breaking abstracts, plenary sessions, and maturing follow-up data, ASH 2025 reflected...